Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults
Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine developme...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | англи |
| Хэвлэсэн: |
2019
|
| Онлайн хандалт: | https://doi.org/10.1093/infdis/jiz518 https://academic.oup.com/jid/article-pdf/222/4/572/33524591/jiz518.pdf |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|